extracts for melanoma treatment research, but before that, a whole extract characterization must be done in order to ensure which compounds are present qualitatively and quantitatively. In addition, expanding the research to other cancer types would be also recommendable.
Reviews are also included in this special issue covering different topics with significant relevance regarding cancer research. Two of these reviews are focused on the pure compound resveratrol. Resveratrol is a stilbene with a long list of biological activities [9] , including cardiovascular disease prevention [10] , UV protection [11] , antiobesity [12] , and anticancer properties [13, 14] . The first review about resveratrol resumes the actual evidence on the epigenetic changes induced by resveratrol in the context of cancer [15] . It underlines the evidence about the epigenetic action of resveratrol on different types of cancer, including breast, lung, cervical, colon, leukemia, lymphoma, and prostate cancers, providing interesting comments about the existing evidence on each case. The second review about resveratrol is more specific, as it focuses on the role of resveratrol in the expression of the miR-663 microRNA and the relationships between this expression, inflammation, and cancer [16] .
Green tea polyphenols have been also reviewed in this special issue. Miyata et al. [17] present in their review an extensive study of the anticancer effects of these polyphenols against bladder cancer. They cover not only in vitro studies using bladder cancer cell lines and in vivo studies using animal models but also new treatment strategies for patients with bladder cancer, based on green tea consumption.
Probiotics are also included in this special issue. Hendler et al. [18] update the previously published evidence on the relationship between probiotics and colon cancer [19, 20] . They have written their review with a special interest on animal and human studies. They conclude that the use of probiotics can be recommended to reduce the colon cancer risk by influencing the microbiome composition. However, a more ambitious study, like a metanalysis must be done to reinforce this conclusion.
A global perspective on the use of natural compounds in cancer treatment is taken by Herranz et al. in their review [21] . In this manuscript, the authors provide an interesting point of view about the relevance of multitargeting and synergy when studying natural compounds. The molecular promiscuity of natural compounds has also been discussed by the same authors [22] , but in this manuscript they focus on cancer, providing advice on experiment design and presenting the advantages and drawbacks when using complex mixtures of natural compounds as extracts. This last point is especially relevant, as there are still some points that must be improved in natural compounds research if we aspire to be considered as seriously as other disciplines are. As mentioned in this review, correct identification of the compounds, extract reproducibility, and bioavailability studies are the main but not the only weal points of natural product research. Better designs for in vivo trials, the use of non-tumor cell lines as controls of in vitro experiments, and synergy studies with other natural and non-natural compounds, especially clinically used drugs, will be welcome.
Finally, this special issue has met its original objective, contributing to increase the scientific evidence on the use of natural compounds in cancer research and treatment. However, there is a long way ahead, and new studies and evidence must be obtained in the future. Nature is a limitless source of new drugs, but these new drugs must always be supported by strong scientific evidence.
